News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cyto Pulse Sciences, Inc., The Karolinska Institute And Uppsala University Hospital Receive Approval from the Swedish Medical Products Agency to Start a Clinical Trial Using a Xenogenic PSA DNA Vaccine


10/13/2008 10:08:34 AM

GLEN BURNIE, Md.--(BUSINESS WIRE)--Cyto Pulse Sciences, a leading producer of electric field based, intradermal DNA Vaccine delivery systems, today announced approval by Swedish regulatory authorities to begin a Phase I/II study of DNA vaccination in patients with recurring prostate cancer. The trial will investigate the safety of a xenogenic DNA vaccine delivered by the Derma Vax™ intradermal electroporation system. The vaccine, which encodes Prostate Specific Antigen (PSA) from a Rhesus Macaque, was developed jointly by Cyto Pulse and the Karolinska Institute and has been licensed to Cyto Pulse.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES